SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (976)12/20/2010 5:12:37 PM
From: nigel bates   of 1022
 
GHENT, Belgium, 8 December 2010 - Ablynx [Euronext Brussels: ABLX] today announced
that Boehringer Ingelheim has selected a Nanobody candidate for development. This is the first
development candidate emerging from the strategic alliance which the companies entered into in
2007, and will result in a €5 million milestone payment to Ablynx.
Ablynx and Boehringer Ingelheim entered into an agreement in September 2007 to collaborate on
the discovery, development and commercialisation of Nanobody therapeutics across a range of
areas including for example immunology, oncology and respiratory diseases. The agreement
allows for potential milestone payments of up to €125 million plus royalties to Ablynx for each
Nanobody developed. Boehringer Ingelheim is exclusively responsible for the development,
manufacture and commercialisation of any products resulting from the collaboration. Ablynx
retains certain co-promotion rights in Europe.

“We are delighted to see this first lead programme progressing into development, just over three
years since we entered into this collaboration with Boehringer Ingelheim,” said Dr Edwin Moses,
CEO and Chairman of Ablynx. He added: “We are particularly pleased as this Nanobody
candidate represents a promising new and innovative approach to potentially expand treatment
options for cancer patients.”
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News